Researchers used genomic structural equation modeling to separate schizophrenia-specific and shared bipolar genetic risks. Schizophrenia-unique variants were linked to lower IQ, while shared variants ...

The FDA OKs pill schizophrenia and bipolar disorder treatment with Bysanti, a new atypical antipsychotic approved for adults.

Bipolar disorder is a psychiatric illness that is characterized by episodes of “mania.” Symptoms include euphoria, distractibility, irritability, and grandiosity. During a manic episode, people often ...

Machine learning models trained on routine clinical data from electronic health records (EHRs) predicted diagnostic progression to schizophrenia or bipolar disorder in patients undergoing treatment in ...

Milsaperidone, a new chemical entity, is the major active metabolite of iloperidone (Fanapt) and had been demonstrated to be bioequivalent to iloperidone.

Please provide your email address to receive an email when new articles are posted on . The best model for predicting schizophrenia performed substantially better than the best bipolar ...

FDA approves evidence-based tool (Bysanti) to address severe mood and psychotic symptoms, which may predict future indications.

Milsaperidone is an active metabolite of iloperidone ...

Schizophrenia and bipolar disorder are serious mental illnesses that affect both males and females, but research in Acta Psychiatrica Scandinavica indicates that sex may influence the characteristics ...

Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.